Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
18:19:38 EDT Wed 08 May 2024
Enter Symbol
or Name
USA
CA



Q:NGNE - NEUROGENE INC - Website unknown - click to update
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
NGNE - Q0.129.49·35.900.132.90-1.04-3.160.71,9221,01232.80  34.7338  32.0053.00  12.4916:00:01May 0715 min RT 2¢

Recent Trades - Last 10 of 1012
Time ETExPriceChangeVolume
16:00:01Q32.90-1.04255
16:00:01Q32.90-1.04200
16:00:01Q32.90-1.04389
16:00:01Q32.90-1.04200
16:00:01Q32.90-1.04200
16:00:01Q32.90-1.0463
16:00:01Q32.90-1.0453
16:00:01Q32.90-1.0413
16:00:01Q32.90-1.0419
16:00:01Q32.90-1.04108

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-05-07 06:19U:NGNENews ReleaseNeurogene Presents Favorable Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome during ASGCT Annual Meeting
2024-04-26 16:14U:NGNESEDAR Annual ReportSEDAR Annual Report
2024-04-22 16:36U:NGNENews ReleaseNeurogene Announces Upcoming Presentation of Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome at ASGCT Meeting
2024-03-28 18:28U:NGNESEDAR Annual ReportSEDAR Annual Report
2024-03-28 18:15U:NGNESEDAR MD & ASEDAR MD & A
2024-03-28 18:09U:NGNESEDAR Audited Annual Financial StatementsSEDAR Audited Annual Financial Statements
2024-03-18 16:14U:NGNENews ReleaseNeurogene Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Updates
2024-03-04 07:30U:NGNENews ReleaseNeurogene Announces Expansion and Plans for More Rapid Patient Enrollment of Rett Syndrome Gene Therapy Clinical Trial
2024-02-29 07:30U:NGNENews ReleaseNeurogene to Participate in Upcoming Investor Conferences
2024-01-16 07:00U:NGNENews ReleaseNeurogene Announces Appointment of Julie Jordan, M.D., as Chief Medical Officer
2024-01-05 07:00U:NGNENews ReleaseNeurogene Announces Business Update and 2024 Outlook
2023-12-19 07:00U:NGNENews ReleaseNeurogene Announces Closing of Merger with Neoleukin Therapeutics and Concurrent Private Placement of $95 Million
2023-12-14 19:00U:NLTXNews ReleaseNeoleukin Therapeutics Announces 1-for-4 Reverse Stock Split
2023-11-14 17:42U:NLTXSEDAR Interim MD & ASEDAR Interim MD & A
2023-11-14 17:41U:NLTXSEDAR Interim Financial StatementsSEDAR Interim Financial Statements
2023-09-22 08:00U:NLTXNews ReleaseNeoleukin Therapeutics Announces 1-for-5 Reverse Stock Split
2023-08-11 18:55U:NLTXSEDAR Interim Financial StatementsSEDAR Interim Financial Statements
2023-07-18 06:30U:NLTXNews ReleaseNeurogene and Neoleukin Announce Definitive Merger Agreement